ArticleEuropean radiology2019
Gliosarcoma: a clinical and radiological analysis of 48 cases.
Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Treatments of gliosarcoma of the brain: a systematic review and meta-analysis.Acta neurologica Belgica · 2021Pooled it
- Gliosarcoma: A Reappraisal of Neuroradiological, Surgical, Morphological, and Radiotherapeutic Characteristics of a Cohort From South Italy Single-Center.Analytical cellular pathology (Amsterdam) · 2026Article
- Opportunities and challenges in application of VASARI features in neuro-oncology.Neuro-oncology practice · 2025Review
- A rare case of gliosarcoma: Comprehensive radiological, histopathological, and clinical insights into diagnosis and management.Radiology case reports · 2025Article
- Diagnostic challenges of gliosarcoma: case report of a rare glioblastoma histopathological variant.Frontiers in radiology · 2025Article
- Differentiating Gliosarcoma from Glioblastoma: A Novel Approach Using PEACE and XGBoost to Deal with Datasets with Ultra-High Dimensional Confounders.Life (Basel, Switzerland) · 2024Article
- Primary Intracranial Gliosarcoma: Is It Really a Variant of Glioblastoma? An Update of the Clinical, Radiological, and Biomolecular Characteristics.Journal of clinical medicine · 2023Review
- Venous ectasia preceding intra-tumoral hemorrhage in a case of gliosarcoma with transverse sinus involvement.Journal of surgical case reports · 2023Article
- Evaluation of postcontrast images of intracranial tumors at 7T and 3T MRI: An intra-individual comparison study.CNS neuroscience & therapeutics · 2023Article
- Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.Computational and mathematical methods in medicine · 2023Article
- Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.Journal of neuro-oncology · 2022Article
- Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Gliosarcoma with direct involvement of the oculomotor nerve: Case report and literature review.Radiology case reports · 2022Article
- Computed Tomography, Magnetic Resonance Imaging, and Pathological Features of Gliosarcoma.Neuropsychiatric disease and treatment · 2022Article
- Do gliosarcomas have distinct imaging features on routine MRI?The neuroradiology journal · 2021Article
- Machine Learning-Based Analysis of Magnetic Resonance Radiomics for the Classification of Gliosarcoma and Glioblastoma.Frontiers in oncology · 2021Article
- PDIA3 correlates with clinical malignant features and immune signature in human gliomas.Aging · 2020Article
- Article
- Article
- Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo retrospectively review the radiological and clinicopathological features of gliosarcoma (GSM) and differentiate it from glioblastoma multiforme (GBM).
methodsThe clinicopathological data and imaging findings (including VASARI analysis) of 48 surgically and pathologically confirmed GSM patients (group 1) were reviewed in detail, and were compared with that of other glioblastoma (GBM) cases in our hospital (group 2).
resultsThere were 28 men and 20 women GSM patients with a median age of 52.5 years (range, 24-80 years) in this study. Haemorrhage (n = 21), a salt-and-pepper sign on T2-weighted images (n = 36), unevenly thickened wall (n = 36) even appearing as a paliform pattern (n = 32), an intra-tumoural large feeding artery (n = 32) and an eccentric cystic portion (ECP) (n = 19) were more commonly observed in the GSM group than in GBM patients. Based on our experience, GSM can be divided into four subtypes according to magnetic resonance imaging (MRI) features. When compared to GBM (group 2), there were more patients designated with type III lesions (having very unevenly thickened walls) and IV (solid) lesions among the GSM cases (group 1). On univariate prognostic analysis, adjuvant therapy (radiotherapy, chemotherapy, and radiochemotherapy) and existence of an eccentric cyst region were prognostic factors. However, Cox's regression model showed only adjuvant therapy as a prognostic factor for GSM.
conclusionsWhen compared to GBM, certain imaging features are more likely to occur in GSM, which may help raise the possibility of this disease. All GSM patients are recommended to receive adjuvant therapy to achieve a better prognosis with radiotherapy, chemotherapy or radiochemotherapy all as options. KEY POINTS: • Diagnosis of gliosarcoma can be suggested preoperatively by imaging. • Gliosarcoma can be divided into four subtypes based on MRI. • Paliform pattern and ECP tend to present in gliosarcoma more than GBM. • The cystic subtype of gliosarcoma may predict a more dismal prognosis. • All gliosarcoma patients should receive adjuvant therapy to achieve better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.